bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 26.14M |
| Revenue (ttm) | 4.94M |
| Net Income (ttm) | -8.37M |
| Shares Out | 11.51M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 129,488 |
| Open | 2.590 |
| Previous Close | 2.450 |
| Day's Range | 2.184 - 2.600 |
| 52-Week Range | 0.955 - 3.620 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2024 |
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas. [Read more]
Financial Performance
In 2023, BIAF's revenue was $2.53 million, an increase of 52627.44% compared to the previous year's $4,803. Losses were -$7.94 million, -2.66% less than in 2022.
Financial StatementsNews
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technology reports record Q1 2024 revenue driven by accelerating sales of lung cancer diagnostic CyPath Lung.
bioAffinity Technologies News Update
SAN ANTONIO--(BUSINESS WIRE)-- #ATS--bioAffinity reports ramp in sales of CyPath® Lung, expanded sales team, new Patient Coach and upcoming presentation at American Thoracic Society.
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is developing diagnostics based on its proprietary platform for use with BAL fluid to detect lung cancer and to detect COPD.
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
SAN ANTONIO--(BUSINESS WIRE)-- #ACS--bioAffinity Technologies and the American Cancer Society are expanding their campaign to raise funds for lung cancer screening.
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports fourth quarter and full year 2023 financial results.
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
JERSEY CITY, N.J. , March 8, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, In...
bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed a securities purchase agreement with institutional investors for gross proceeds of approximately $2.5 million.
WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
JERSEY CITY, N.J. , March 6, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BioAffinity Technologies (NA...
bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces it has entered into a securities purchase agreement with institutional investors.
bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports 375% growth in sales of CyPath Lung tests in recent months.
Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies' Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Sandeep Bansal, M.D., joins bioAffinity Medical and Science Advisory Board; adds CyPath Lung to his practice.
bioAffinity Technologies In The News
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Summary of the latest news about bioAffinity Technologies.
bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Indian Patent Office issues patent to bioAffinity Technologies for porphyrin compounds related to targeted cancer treatment.
bioAffinity Technologies In the News
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--A summary of latest news about bioAffinity Technologies and CyPath® Lung, its noninvasive test for the detection of early-stage lung cancer.
bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Mone...
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Jamie Platt, Ph.D., joins the bioAffinity Technologies Board of Directors.
CMS Posts Final Payment Determination for bioAffinity Technologies' CyPath® Lung Effective January 2024
SAN ANTONIO,--(BUSINESS WIRE)-- #BIAF--CMS has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.
bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
SAN ANTONIO--(BUSINESS WIRE)-- #ASCB--bioAffinity Technologies VP of Research David Elzi, Ph.D., named to post with the American Society for Cell Biology.
bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today launched a campaign in partnership with the ACS to increase lung cancer screening in Texas.
bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports third quarter 2023 financial results and provides business update.
bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces the appointment of Dallas Coleman as National Director of Sales.
bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents at Dawson James Small Cap Growth Conference this week.
bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, ann...
bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity President and CEO Maria Zannes will present at H.C. Wainwright Global Investment Conference Sept. 11-13.
bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports second quarter 2023 financial results and provides business update.